Format

Send to

Choose Destination
N Engl J Med. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25.

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

Collaborators (170)

Tan H, Hovey E, Mainwaring P, Steer C, Marx G, deSouza P, Davis I, Begbie S, Nott L, Pook D, Cuff K, Epstein R, Gurney H, Schmidinger M, Loidl W, De Santis M, Gil T, Wynendaele W, Demey W, Schöffski P, Knox J, Soulieres D, Czaykowski P, Basappa N, Kollmannsberger C, Bjarnason G, Wood L, Zalewski P, Hotte S, Heng D, Winquist E, Salman P, Frontera O, Katolicka J, Melichar B, Jensen N, Geertsen P, Donskov F, Peltola K, Escudier B, Gravis G, Joly F, Chevreau C, Oudard S, Laguerre B, Rolland F, Voog E, Negrier S, Maurina T, Goupil M, Staehler M, Pfister D, Rink M, Gruenwald V, Retz M, Wirth M, Schultze-Seemann W, Depenbusch R, Schnöller T, Bergmann L, Gruellich C, Csoszi T, Geczi L, McCaffrey J, McDermott R, Sternberg C, Passalacqua P, De Giorgi U, Sabbatini R, Boccardo F, Carrozza F, Roila F, Santini D, Bracarda S, van Thienen J, Aarts M, Osanto S, Tomczak P, Pikiel J, Wojtukiewicz M, Szczylik C, Sousa N, Coelho J, Costa L, Cheporov S, Kopyltsov E, Nosov D, Mincik I, Mikulas J, Rha S, Keam B, Lee J, Park S, Grande E, Chirivella I, Solans XG, Suarez C, Duran I, Castellano D, Garcia Donas J, Perez Gracia J, Martinez A, Medina M, Maroto P, Gonzalez E, Harmenberg U, Thomasson M, Blom R, Lin C, Chang Y, Ou Y, Sevinc A, Dane F, Gokmen E, Yildiz R, Hawkins R, Hussain S, Larkin J, Nathan P, Porfiri E, Malik J, MacDonald A, Powles T, Chowdhury S, Glen H, Motzer R, Choueiri T, Geynisman D, Kluger H, Appleman L, Shaffer D, Fishman M, Hainsworth J, Sonpavde G, Drabkin H, Hammers H, George D, Merchan J, Hussain A, Koletsky A, Hanna W, Troner M, Vaishampayan U, Costello B, Olencki T, Vaena D, Redman B, Rini B, Stadler W, Roth B, Tannir N, Kuzel T, Wright J, Hutson T, Van Veldhuizen P, Richey S, Doshi G, Sarantopoulos J, Ryan C, Samlowski W, Tykodi S, Pal S, Agarwal N, Kabbinavar F, Figlin R, Ho T, Wong B, Singh P, Kolevska T, Randall J.

Author information

1
From the Dana-Farber Cancer Institute, Boston (T.K.C., P.W.K.); Institut Gustave Roussy, Villejuif, France (B.E.); Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, London (T.P.); Icon Cancer Care, South Brisbane, QLD, Australia (P.N.M.); Cleveland Clinic, Cleveland (B.I.R.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (H.H.); Texas Oncology-Charles A. Sammons Cancer Center, Baylor University, Dallas (T.E.H.); University of Ulsan College of Medicine (J.-L.L.) and Seoul National University Hospital (B.K.) - both in Seoul, South Korea; Helsinki University Central Hospital Cancer Center, Helsinki (K.P.); Washington University in St. Louis, St. Louis (B.J.R.); Sunnybrook Odette Cancer Centre, Toronto (G.A.B.), and Tom Baker Cancer Centre, Calgary, AB (D.Y.C.H.) - both in Canada; National Institute of Oncology, Budapest, Hungary (L.G.); Hospital de la Santa Creu i Sant Pau, Barcelona (P.M.); Medical University of Vienna, Vienna (M.S.); Exelixis, South San Francisco, CA (A.B-H., C.H., C.S., G.M.S.); University of Texas M.D. Anderson Cancer Center, Houston (N.M.T.); and the Memorial Sloan Kettering Cancer Center, New York (R.J.M.).

Abstract

BACKGROUND:

Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which has been implicated in the pathobiology of metastatic renal-cell carcinoma or in the development of resistance to antiangiogenic drugs. This randomized, open-label, phase 3 trial evaluated the efficacy of cabozantinib, as compared with everolimus, in patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy.

METHODS:

We randomly assigned 658 patients to receive cabozantinib at a dose of 60 mg daily or everolimus at a dose of 10 mg daily. The primary end point was progression-free survival. Secondary efficacy end points were overall survival and objective response rate.

RESULTS:

Median progression-free survival was 7.4 months with cabozantinib and 3.8 months with everolimus. The rate of progression or death was 42% lower with cabozantinib than with everolimus (hazard ratio, 0.58; 95% confidence interval [CI] 0.45 to 0.75; P<0.001). The objective response rate was 21% with cabozantinib and 5% with everolimus (P<0.001). A planned interim analysis showed that overall survival was longer with cabozantinib than with everolimus (hazard ratio for death, 0.67; 95% CI, 0.51 to 0.89; P=0.005) but did not cross the significance boundary for the interim analysis. Adverse events were managed with dose reductions; doses were reduced in 60% of the patients who received cabozantinib and in 25% of those who received everolimus. Discontinuation of study treatment owing to adverse events occurred in 9% of the patients who received cabozantinib and in 10% of those who received everolimus.

CONCLUSIONS:

Progression-free survival was longer with cabozantinib than with everolimus among patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy. (Funded by Exelixis; METEOR ClinicalTrials.gov number, NCT01865747.).

PMID:
26406150
PMCID:
PMC5024539
DOI:
10.1056/NEJMoa1510016
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center